---
figid: PMC4229247__nihms639347f4
figtitle: Pathways for initiation and maintenance of psoriasis
organisms:
- Nicotiana tabacum
- Candida albicans
- Candida albicans 23R
- Candida albicans 23P
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Danio rerio
pmcid: PMC4229247
filename: nihms639347f4.jpg
figlink: /pmc/articles/PMC4229247/figure/F4/
number: F4
caption: 'Pathways for initiation and maintenance of psoriasis. (a) Early disease:
  Imiquimod (IMQ), a TLR7 agonist, can activate plasmacytoid dendritic cells (pDCs)
  to produce interferons (IFN). LL37, a peptide derived from cathelicidin, may have
  an important role in the initiation of psoriasis lesions via this pathway. LL37
  released from keratinocytes (KCs) can bind to nucleic acids to activate pDCs to
  release IFN-α/β. LL37/RNA complexes can also activate resident myeloid DCs to produce
  IL-12 and IL-23, key psoriatic cytokines. (b) Chronic disease: The major pathogenic
  pathway in psoriasis occurs when (I) mature dermal DCs and inflammatory myeloid
  DCs produce cytokines such as IL-23 and IL-12. (II) These cytokines activate T17
  (Th17 and Tc17), Th1, and Th22 cells to contribute to the cytokine milieu and further
  act on keratinocytes. (III) As outlined in , keratinocytes can produce chemokines
  and antimicrobial peptides (AMPs) to (IV) augment cutaneous immune responses.'
papertitle: Immunology of Psoriasis.
reftext: Michelle A. Lowes, et al. Annu Rev Immunol. ;32:227-255.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9006491
figid_alias: PMC4229247__F4
figtype: Figure
redirect_from: /figures/PMC4229247__F4
ndex: ef06de46-deab-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4229247__nihms639347f4.html
  '@type': Dataset
  description: 'Pathways for initiation and maintenance of psoriasis. (a) Early disease:
    Imiquimod (IMQ), a TLR7 agonist, can activate plasmacytoid dendritic cells (pDCs)
    to produce interferons (IFN). LL37, a peptide derived from cathelicidin, may have
    an important role in the initiation of psoriasis lesions via this pathway. LL37
    released from keratinocytes (KCs) can bind to nucleic acids to activate pDCs to
    release IFN-α/β. LL37/RNA complexes can also activate resident myeloid DCs to
    produce IL-12 and IL-23, key psoriatic cytokines. (b) Chronic disease: The major
    pathogenic pathway in psoriasis occurs when (I) mature dermal DCs and inflammatory
    myeloid DCs produce cytokines such as IL-23 and IL-12. (II) These cytokines activate
    T17 (Th17 and Tc17), Th1, and Th22 cells to contribute to the cytokine milieu
    and further act on keratinocytes. (III) As outlined in , keratinocytes can produce
    chemokines and antimicrobial peptides (AMPs) to (IV) augment cutaneous immune
    responses.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Mthfd1
  - Ass1
  - Cd4
  - Il23a
  - Il17a
  - Tnf
  - Il17f
  - Il21
  - Tlr9
  - Tlr7
  - Ifna
  - Hand1
  - Nelfcd
  - Il22
  - ASS1
  - CD4
  - CD8A
  - CD8B
  - TBCE
  - IL37
  - IL23A
  - IL17A
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - TNF
  - ADSL
  - IL17F
  - IL22
  - IL21
  - CAMP
  - IL12A
  - IL12B
  - TLR9
  - TLR7
  - IFNA1
  - NELFCD
  - TCN1
  - SLC19A2
  - TCIM
  - ass1
  - ighv1-1
  - cd4-1
  - tnfrsfa
  - tnfb
  - il21
  - tlr9
  - tlr7
  - ifnphi1
  - il22
  - atp1b1a
---
